Pacira BioSciences Inc

Pacira BioSciences faces a Bronstein‑Gewirtz probe, raising questions on its non‑opioid pain platform, stock volatility, and future growth amid regulatory scrutiny.

Pacira BioSciences reports positive two-year efficacy data for PCRX-201, a non-opioid pain therapy, showing sustained improvements in knee pain, stiffness, and function for up to two years in patients with mild to severe osteoarthritis.